Abstract:Background: Inflammatory cytokines in the tumor microenvironment (TME) contribute to tumor growth, pro-liferation, and invasion, and tumor-derived extracellular vesicles (EVs) act as critical "messengers" of commu-nication in the tumor microenvironment. The effects of EVs derived from oral squamous cell carcinoma (OSCC) cells on tumor progression and the inflammatory microenvironment are still unclear. Our study aims to inves-tigate the role of OSCC-derived EVs in tumor progression, the imbalanced TME, and immunosuppression and their effect on the IL-17A-induced signaling pathway. Methods: EVs were isolated from the supernatant of a mouse OSCC cell line, SCC7. The effects of SCC7-EVs and the EV release-specific inhibitor GW4869 on the proliferation and migration of SCC7 cells were investigated in vitro by using CCK-8 and scratch wound healing assays. RT-qPCR and ELISA were performed to examine the alterations in cytokine levels. Then, a mouse xenograft model of OSCC was established by submucosal injection of SCC7 cells with or without SCC7-EV and GW4869 treatment. The effects of GW4869 and SCC7-EVs on xenograft tumor proliferation and invasion were investigated by tumor volume determination and histopatho-logical examination. ELISA was used to investigate the changes in serum cytokine levels. Immunohistochemistry was adopted to analyze the alterations in the levels of inflammatory cytokines, immune factors, and crucial molecules in the IL-17A signaling pathway. Results: SCC7-derived EVs increased the supernatant and serum levels of IL-17A, IL-10, IL-1 beta, and PD-L1, while GW4869 decreased those of TNF-alpha and IFN-gamma. SCC7-EV treatment significantly increased xenograft tumor growth and invasion in mice but resulted in little liquefactive necrosis in tumors. However, GW4869 treatment signif-icantly inhibited xenograft tumor growth but resulted in more liquefactive necrosis. SCC7-derived EVs decreased the expression level of PTPN2, suppressing the immune responses of CD8 + T cells in vivo. Moreover, SCC7-EV treatment significantly enhanced the tumor expression levels of crucial molecules in the IL-17A pathway, including IL-17A, TRAF6 and c-FOS, whereas GW4869 treatment significantly reduced those levels in tumor tissues. Conclusion: Our results indicated that OSCC-derived EVs can promote tumor progression by altering the TME, causing an inflammatory cytokine imbalance, inducing immunosuppression, and contributing to overactivation of the IL-17A-induced signaling pathway. Our study might provide novel insights into the role of OSCC-derived EVs in tumor biological behavior and immune dysregulation.

Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab Therapy

Abstract 365: Autocrine Vascular Endothelial Growth Factor Signaling Mediates Survival and Chemoresistance of Human Colorectal Cancer Cells

Small extracellular vesicle-bound vascular endothelial growth factor secreted by carcinoma-associated fibroblasts promotes angiogenesis in a bevacizumab-resistant manner

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Extracellular Vesicle-Mediated Chemoresistance in Oral Squamous Cell Carcinoma

Extracellular vesicles in oral squamous cell carcinoma: current progress and future prospect

Oral Squamous Cell Carcinoma-Derived EVs Promote Tumor Progression by Regulating Inflammatory Cytokines and the IL-17A-induced Signaling Pathway

Advances in the Biological Functions of Extracellular Vesicles and their Potential Use in Treating Oral Cancer

[Expression of Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor-3 and Nm23-H1 in Oral Squamous Cell Carcinoma].

Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects

Role of Vascular Endothelial Growth Factor in Radiotherapy Resistance to Esophageal Squamous Cell Carcinoma

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

Ovarian cancer exosome-mediated evasion of the anti-angiogenic effect of bevacizumab

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

Vascular endothelial growth factor pathway's influence on bevacizumab efficacy in metastatic colorectal cancer treatment

Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer

Exosomes and other extracellular vesicles in oral and salivary gland cancers

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Extracellular vesicles from oral squamous carcinoma cells display pro- and anti-angiogenic properties

Gamma-synuclein Promotes Bevacizumab Resistance by Activating Vascular Endothelial Growth Factor Receptor in Colorectal Cancer

Extracellular vesicles promote activation of pro-inflammatory cancer-associated fibroblasts in oral cancer